Skip to main content

Table 1 Patient population description

From: A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis

  Dendritics cell vaccine (n = 8) Observation (n = 7)
Age (mean, CI 95%) 58.75 (52.25–65.25) 56.29 (52.92–69.66)
Sex (%)
 Male 50% 62.5%
 Female 50% 37.5%
ECOG (median, range) 0 (0–1) 0 (0–1)
ESMO (median, range) 1 (0–1) 0 (0–1)
Köhne (median, range) 0 (0–1) 0 (0)
Nagashima score (%)
 Low risk 0% 50%
 Moderate risk 33.33% 50%
 High risk 66.67% 0%
Fong score (%)
 Low risk 50% 57.14%
 High risk 50% 42.86%
Histology (%)
 Adenocarcinoma 87.5% 100%
 Mucinous 12.5% 0%
CEA (%)
  < 200 ng/ml 50% 85.7%
  > 200 ng/ml 50% 14.3%
Metastatic disease at diagnosis 87.5% 57.4%
Neoadjuvant cycles (mean, CI 95%) 5.75 (4.68–6.82) 6.57 (5.67–7.47)
KRAS status
 Mutant 62.5% 57.14%
 Wild type 37.5% 42.6%
 MSI status 37.5% 0%